New drug cuts seizures by up to 91% in children with rare epilepsy
An experimental drug called zorevunersen shows significant promise for children with Dravet syndrome by reducing seizures up to 91% and improving quality of life through enhanced gene function in nerve cell signaling. Positive trial results have prompted researchers to advance to larger Phase 3 clinical trials.




